Cubist settlement with Teva boosts stock; Study finds possible link between HPV, lung cancer;

@FiercePharma: Data questions Avastin safety for eye use. Report | Follow @FiercePharma

> Cubist Pharmaceuticals stock surged after the company reached a licensing deal with Teva Pharmaceutical Industries, allowing the Israeli generics maker to sell a knock-off version of its Cubicin antibiotic beginning in 2017 or 2018. Story

> Human papillomavirus (HPV), a common sexually transmitted virus that accounts for most cases of cervical cancer--and is also targeted by two Big Pharma vaccines--may also play a role in lung cancer, researchers report. News

> The House Republican plan for overhauling Medicare would fundamentally change how the federal government pays for health care, resulting in higher out-of-pocket costs and greater limits to coverage for many Americans. Story

> The latest study on estrogen sends complex signals about the effects of the hormone on women who have had hysterectomies, with those who started therapy in their 70s experiencing "potential harm" while women in their 50s didn't. Report

> Medicis Pharmaceutical said Iceland-based drugmaker Actavis has filed with U.S. health regulators for a copycat version of its acne drug Ziana. Article

> AstraZeneca and UCB officially signed previously-negotiated agreements with Russian companies to facilitate development of biotechnology on the local pharmaceutical market. Item

> Canada's Angiotech Pharmaceuticals said its creditors had approved a restructuring plan to cut $250 million of its debt. Item

> Six months of therapy using Plavix and aspirin to prevent dangerous blood clots from forming in stents following artery-clearing procedures may be as effective as current guidelines calling for 12 months or longer. Article

> Gilead Sciences' heart drug Ranexa, while found to be effective in reducing chest pain in refractory angina patients, failed to cut hospitalizations in a small 100-patient study. Story

Biotech News

 @FierceBiotech: Gene-patent courtroom drama plays out in Washington. Report | Follow @FierceBiotech 

 @JohnCFierce: Optimer is also hiring 100 reps for fidaxomicin, to be sold as Dificid. (Dificid?) Article | Follow @JohnCFierce

> Optimer readies antibiotic campaign after winning FDA panel vote. News

> Chinese billionaire backs $100M U.S./China biotech launch. Report

> Aldagen drops second IPO as Sagent mounts $80M offering. News

> Struggling Capstone delays key data analysis on lead drug. Item

Drug Delivery News

> Semiconductor technique could attack MRSA. Report

> MonoSol aims for asthma market with thin film. Article

> Morphotek acquires TMI's scorpion venom platform. Item

> Silicon Valley makes 'first' investment in Belfast startup. Story

> Texas researchers find a better way of deliverying siRNA. News

> Mucus lets toxins in, but could also let in hydrophobic drugs. Article

Medical Device News

> Wright Medical's CEO, CTO out. News 

> CareFusion's COO to leave this summer. Article

> Nevada officials look into Biotronik payments to docs. Report 

> Unilife realigns operations, looks to save $12M. Story

> Neuros Medical reports positive results from pain study. Item 

> Cappella taps Shea as CEO. News

And Finally... The U.S. Supreme Court blocked the first scheduled execution of a Texas death row inmate using a new drug cocktail, although the proposed lethal mix was not mentioned in the court's decision to reconsider the merits of the condemned man's appeal. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.